Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27741282 | 0.81 | PPM1D (0.50) | PPM1DKMT2A | |
| SCHEMBL28048040 | 0.79 | PPM1D (0.48) | PPM1DALDH1A1KMT2A | |
| SCHEMBL4941110 | 0.79 | ALDH1A1 (0.68) | ALDH1A1LMNATDP1SLC6A2SLC6A3 | |
| SCHEMBL4938474 | 0.78 | ALDH1A1 (0.71) | ALDH1A1LMNATDP1SLC6A2SLC6A3 | |
| SCHEMBL28105519 | 0.77 | PPM1D (0.45) | PPM1DALDH1A1KMT2A | |
| SCHEMBL5834481 | 0.76 | ALDH1A1 (0.62) | ALDH1A1LMNATDP1SLC6A2SLC6A3 | |
| SCHEMBL5834914 | 0.76 | ALDH1A1 (0.71) | ALDH1A1LMNATDP1SLC6A2SLC6A3 | |
| SCHEMBL3853181 | 0.74 | PPM1D (0.51) | PPM1DKMT2A | |
| SCHEMBL7298560 | 0.74 | PPM1D (0.53) | PPM1DALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL28047118 | 0.74 | KDM4E (0.42) | PPM1DALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | PPM1D 1382/4885ALDH1A1 3323/4885LMNA 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.